C
Christopher K. Finch
Researcher at University of Tennessee Health Science Center
Publications - 69
Citations - 1770
Christopher K. Finch is an academic researcher from University of Tennessee Health Science Center. The author has contributed to research in topics: COPD & Rifabutin. The author has an hindex of 16, co-authored 65 publications receiving 1588 citations. Previous affiliations of Christopher K. Finch include University of Alabama & Methodist University.
Papers
More filters
Journal ArticleDOI
The clinical and economic burden of chronic obstructive pulmonary disease in the USA.
TL;DR: With more than 50 new medications in the pipeline for the treatment of COPD, optimal management will continue to evolve and grow more complex as benefits of therapy are balanced with the limitations and needs of each patient.
Journal ArticleDOI
Rifampin and Rifabutin Drug Interactions: An Update
TL;DR: Clinicians need to be cognizant of rifampin and rifabutin interactions to avoid a reduced therapeutic response, therapeutic failure, or toxic reactions when rifampsin is added to or discontinued from medication regimens.
Journal ArticleDOI
Update on rifampin, rifabutin, and rifapentine drug interactions
TL;DR: To avoid a reduced therapeutic response, therapeutic failure, or toxic reactions when rifampin, rifabutin, or rifapentine are added to or discontinued from medication regimens, clinicians need to be aware of these interactions.
Journal ArticleDOI
Fondaparinux for the treatment of patients with acute heparininduced thrombocytopenia
TL;DR: This pilot study suggests that fondaparinux may be useful in patients with acute HIT and indicates that limb gangrene in historical controls may have been a result of delayed recognition of HIT and/or inappropriately early institution of warfarin in the historical controls.
Journal ArticleDOI
Update on rifampin and rifabutin drug interactions.
TL;DR: To avoid a decreased therapeutic response, therapeutic failure, or toxic reactions when rifampin is added to or discontinued from medication regimens, clinicians need to be cognizant of these interactions.